Drugs

, Volume 63, Issue 4, pp 353–365 | Cite as

Extended Spectrum β-Lactamase (ESBL)-Producing Enterobacteriaceae

Considerations for Diagnosis, Prevention and Drug Treatment
Leading Article

Abstract

Extended spectrum β-lactamase (ESBL)-producing organisms pose unique challenges to clinical microbiologists, clinicians, infection control professionals and antibacterial-discovery scientists. ESBLs are enzymes capable of hydrolysing penicillins, broad-spectrum cephalosporins and monobactams, and are generally derived from TEM and SHV-type enzymes. ESBLs are often located on plasmids that are transferable from strain to strain and between bacterial species. Although the prevalence of ESBLs is not known, it is clearly increasing, and in many parts of the world 10–40% of strains of Escherichia coli and Klebsiella pneumoniae express ESBLs.

ESBL-producing Enterobacteriaceae have been responsible for numerous outbreaks of infection throughout the world and pose challenging infection control issues. Clinical outcomes data indicate that ESBLs are clinically significant and, when detected, indicate the need for the use of appropriate antibacterial agents. Unfortunately, the laboratory detection of ESBLs can be complex and, at times, misleading.

Antibacterial choice is often complicated by multi-resistance. Many ESBL-producing organisms also express AmpC β-lactamases and may be co-transferred with plasmids mediating aminoglycoside resistance. In addition, there is an increasing association between ESBL production and fluoroquinolone resistance. Although in in vitro tests ESBLs are inhibited by β-lactamase inhibitors such as clavulanic acid, the activity of β-lactam/β-lactamase inhibitor combination agents is influenced by the bacterial inoculum, dose administration regimen and specific type of ESBL present. Currently, carbapenems are regarded as the drugs of choice for treatment of infections caused by ESBL-producing organisms. Unfortunately, use of carbapenems has been associated with the emergence of carbapenem-resistant bacterial species such as Stenotrophomonas sp. or Pseudomonas sp.

Keywords

Minimum Inhibitory Concentration Cefotaxime Ceftazidime Clavulanic Acid Cefepime 

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Knothe H, Shah P. Kremery V, et al. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315–7PubMedCrossRefGoogle Scholar
  2. 2.
    Jacoby GA, Medeiros AA, O’Brien TF, et al. Broad-spectrum, transmissible β-lactamases. N Engl J Med 1988; 319: 723–4PubMedCrossRefGoogle Scholar
  3. 3.
    Quinn JR, Miyashiro D, Sahm D, et al. Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989; 33: 1451–6PubMedCrossRefGoogle Scholar
  4. 4.
    Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 48: 933–51CrossRefGoogle Scholar
  5. 5.
    Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39: 1211–33PubMedCrossRefGoogle Scholar
  6. 6.
    Mugnier PI, Casin I, Casin G, et al. A TEM-derived extended-spectrum β-lactamase in pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 2488–93PubMedGoogle Scholar
  7. 7.
    Naas T, Philippon L, Poirel L, et al. An SHV-derived extended-spectrum beta-lactamase in pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 1281–4PubMedGoogle Scholar
  8. 8.
    Rosenau A, Cattier B, Gousset N, et al. Capnocytophaga ochracea: characterization of a plasmid encoded extended-spectrum TEM-17 β-lactamase in the phylum Flavobacter-Bacteroides. Antimicrob Agents Chemother 2000; 44: 760–2PubMedCrossRefGoogle Scholar
  9. 9.
    Philippon A, Arlet B, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 2002; 46: 1–11PubMedCrossRefGoogle Scholar
  10. 10.
    Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557–84PubMedGoogle Scholar
  11. 11.
    Matthew M, Hedges RW. Analytical isoelectric focusing of R factor determined β-lactamases: correlation with plasmid compatibility. J Bacteriol 1976; 125: 713–8PubMedGoogle Scholar
  12. 12.
    Huovinen PS, Huovinen S, Jacoby GA. Sequence of PSE-2 β-lactmase. Antimicrob Agents Chemother 1988; 32: 134–6PubMedCrossRefGoogle Scholar
  13. 13.
    Bauernfeind A, Stemplinger I, Jungwirth R, et al. Sequences of β-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other β-lactamases. Antimicrob Agents Chemother 1996; 40: 509–13PubMedGoogle Scholar
  14. 14.
    Bauernfeind A, Stemplinger I, Jungwirth R, et al. Characterization of β-lactamase gene blaPER-2, which encodes an extended-spectrum class A β-lactamase. Antimicrob Agents Chemother 1996; 40: 616–20PubMedGoogle Scholar
  15. 15.
    Nordman PE, Ronco T, Naas C, et al. Characterization of a novel extended-spectrum β-lactamase from pseudomonas aeruginosa. Antimicrob Agents Chemother 1993; 37: 962–9CrossRefGoogle Scholar
  16. 16.
    Vedel GA, Belaaouaj L, Gilly R, et al. Clinical isolates of Escherichia coli producing TRI β-lactamases: novel TEM-enzymes conferring resistance to β-lactamase inhibitors. J Antimicrob Chemother 1992; 30: 449–62PubMedCrossRefGoogle Scholar
  17. 17.
    Chaibi EB, Sirot D, Paul G, et al. Inhibitor-resistant TEM-β-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999; 43: 447–58PubMedCrossRefGoogle Scholar
  18. 18.
    National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A5 and informational supplement M100-S12. Wayne (PA): National Committee for Clinical Laboratory Standards, 2000Google Scholar
  19. 19.
    National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: approved standard M100-S9. Wayne (PA): National Committee for Clinical Laboratory Standards, 1999Google Scholar
  20. 20.
    Thomson KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis 2001; 7: 333–6PubMedCrossRefGoogle Scholar
  21. 21.
    Steward CD, Rasheed JK, Hubert SK, et al. Characterization of clinical isolates of Klebsiella pneumoniae from 19 clinical laboratories using the national Committee for Clinical Laboratory Standards Extended-spectrum β-lactamase detection methods. J Clin Microbiol 2001; 39: 2864–72PubMedCrossRefGoogle Scholar
  22. 22.
    Thomson KS, Sanders CC, Moland ES. Use of microdilution panels with and without β-lactamase inhibitors as a phenotypic test for β-lactamase production among Escherichia coli, Klebsiella spp, Enterobacter spp., Citrobacter freundii, and Serratia marcescens. Antimicrob Agents Chemother 1999; 43: 1393–400PubMedGoogle Scholar
  23. 23.
    Tzelepi EP, Giakkoupi D, Sofianou V, et al. Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. J Clin Microbiol 2000; 38: 542–6PubMedGoogle Scholar
  24. 24.
    Jarlier V, Nicolas MH, Fournier G, et al. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867–8PubMedCrossRefGoogle Scholar
  25. 25.
    Thomson KS, Sanders CC. Detection of extended-spectrum β-lactamases in members of the family Enterobacteriaceae: comparison of the double-disk and three-dimensional tests. Antimicrob Agents Chemother 1992; 36: 1877–82PubMedCrossRefGoogle Scholar
  26. 26.
    Vercauteren E, Descheemaeker P, Ieven M, et al. Comparison of screening methods for detection of extended-spectrum β-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian Teaching hospital. J Clin Microbiol 1997; 35: 2191–7Google Scholar
  27. 27.
    Cormican MG, Marshall SA, Jones RN. Detection of extended-spectrum β-lactamase (ESBL)-producing strains by the E-test ESBL screen. J Clin Microbiol 1996; 34: 1880–4PubMedGoogle Scholar
  28. 28.
    Sanders CC, Peyret M, Moland ES, et al. Ability of VITEK 2 advanced expert system to identify β-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa. J Clin Microbiol 2000; 38: 570–4PubMedGoogle Scholar
  29. 29.
    Sanders CC, Barry AL, Washington JA, et al. Detection of extended-spectrum β-lactamase-producing members of the family Enterobacteriaceae with the Vitek ESBL test. J Clin Microbiol 1996; 34: 2997–3001PubMedGoogle Scholar
  30. 30.
    Livermore DM, Struelens M, Amorim J, et al. Multicentre evaluation of Vitek 2 advanced expert system for interpretive reading of antimicrobial resistance tests. J Antimicrob Chem-other 2002; 49: 289–300CrossRefGoogle Scholar
  31. 31.
    Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45: 3548–54PubMedCrossRefGoogle Scholar
  32. 32.
    Brun-Buisson C, Legrand P, Philippon A, et al. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 1987; II: 302–6CrossRefGoogle Scholar
  33. 33.
    Karas JA, Pillay DG, Muckart D, et al. Treatment failure due to extended spectrum beta-lactamase. J Antimicrob Chemother 1996; 37: 203–4PubMedCrossRefGoogle Scholar
  34. 34.
    Venezia RA, Scarano FJ, Preston KE, et al. Molecular epidemiology of an SHV-5 extended-spectrum beta-lactamase in Enterobacteriaceae isolated from infants in a neonatal intensive care unit. Clin Infect Dis 1995; 21: 915–23PubMedCrossRefGoogle Scholar
  35. 35.
    Rice LB, Eckstein EC, DeVente J, et al. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23: 118–24PubMedCrossRefGoogle Scholar
  36. 36.
    Patterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infectious due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39: 2206–12CrossRefGoogle Scholar
  37. 37.
    Tenover FC, Mohammed MJ, Gorton TS, et al. Detection and reporting of organisms producing extended-spectrum beta-lactamases: survey of laboratories in Connecticut. J Clin Microbiol 1999; 37: 4065–70PubMedGoogle Scholar
  38. 38.
    Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp collected from intensive care units in Southern and Western Europe in 1997–1998. J Antimicrob Chemother 2000; 45: 183–9PubMedCrossRefGoogle Scholar
  39. 39.
    Stobberingh EE, Arends J, Hoogkamp-Korstanje JAA, et al. Occurrence of extended-spectrum β-lactamases in Dutch hospitals. Infection 1999; 27: 348–54PubMedCrossRefGoogle Scholar
  40. 40.
    Branger C, Lesimple CA, Bruneu B, et al. 1. Long-term investigation of the clonal dissemination of Klebsiella pneumoniae isolates producing extended-spectrum β-lactamases in a university hospital. J Med Microbiol 1998; 47: 210–09CrossRefGoogle Scholar
  41. 41.
    Jacoby GA. Extended-spectrum β-lactamases and other enzymes providing resistance to oxyimino β-lactams. Infect Dis Clin North Am 1997; 11: 875–87PubMedCrossRefGoogle Scholar
  42. 42.
    Selected antimicrobial resistant pathogens associated with nosocomial infections in ICU patients, comparisons of resistance rates scan January–December 1999 with 1994–1998. Available from URL: http://www.cdc.gov/ncidod/hip/NNIS/june2000sar [Accessed 2002 Feb 4]
  43. 43.
    Winokur PL, Canton R, Casellas JM, et al. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the western pacific region. Clin Infect Dis 2001; 32 Suppl. 2: S94–103PubMedCrossRefGoogle Scholar
  44. 44.
    Lewis MT, Gales AC, Sader HS, et al. Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with diagnosis of pneumonia: results from the SENTRY antimicrobial surveillance program (1998). Diagn Microbiol Infect Dis 2000; 37: 63–74PubMedCrossRefGoogle Scholar
  45. 45.
    Pfaller MA, Jones RN, Doern GV, et al. Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia: comparison of data from 1997 and 1998 using the E test method. Diagn Microbiol Infect Dis 1999; 35: 235–41PubMedCrossRefGoogle Scholar
  46. 46.
    Bell JM, Turnidge JD, Gales AC, et al. Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY antimicrobial surveillance program (1998–99). Diagn Microbiol Infect Dis 2002; 42: 193–8PubMedCrossRefGoogle Scholar
  47. 47.
    Jones RN. Summation: β-Lactam resistance surveillance in the Asia-western pacific region. Diagn Microbiol Infect Dis 1999; 35: 333–8PubMedCrossRefGoogle Scholar
  48. 48.
    Biedenbach DJ, Lewis MT, Jones RN. In vitro evaluation of Cefepime and other broad-spectrum β-lactams for isolates in Malaysia and Singapore medical centers. Diagn Microbiol Infect Dis 1999; 35: 277–83PubMedCrossRefGoogle Scholar
  49. 49.
    Johnson DM, Biedenbach DJ, Jones RN. In vitro evaluation of broad spectrum β-lactams in the Philippines medical centers: role of fourth-generation cephalosporins. Diagn Microbiol Infect Dis 1999; 35: 291–7PubMedCrossRefGoogle Scholar
  50. 50.
    Lewis MT, Biedenbach DJ, Jones RN. In vitro evaluation of broad-spectrum β-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins. Diagn Microbiol Infect Dis 1999; 35: 317–23PubMedCrossRefGoogle Scholar
  51. 51.
    Cotton MF, Wasserman E, Pieper CH. Invasive disease due to extended-spectrum β-lactamase producing Klebsiella pneumoniae in a neonatal unit: the possible role of cockroaches. J Hosp Infect 2000; 44: 13–7PubMedCrossRefGoogle Scholar
  52. 52.
    Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119: 353–8PubMedGoogle Scholar
  53. 53.
    Naumovski L, Quinn JP, Miyashiro D, et al. Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992; 36: 1991–6PubMedCrossRefGoogle Scholar
  54. 54.
    Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case-control and molecular epidemiologic investigation. J Infect Dis 1996; 174: 529–36PubMedCrossRefGoogle Scholar
  55. 55.
    Emery CL, Weymouth LA. Detection and clinical significance of extended-spectrum β-lactamases in a tertiary-care medical center. J Clin Microbiol 1997; 35: 2061–7PubMedGoogle Scholar
  56. 56.
    Medeiros AA, Crelin J. Comparative susceptibility of clinical isolates producing extended-spectrum β-lactamases to ceftibuten: effect of a large inoculum. Pediatr Infect Dis J 1997; 16: S49–S55PubMedCrossRefGoogle Scholar
  57. 57.
    Caron F, Gutmann L, Bure A, et al. Ceftriaxone-sulbactam combination in a rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended broad spectrum TEM-3 β-lactamase. Antimicrob Agents Chemother 1990; 34: 2070–4PubMedCrossRefGoogle Scholar
  58. 58.
    Rice LB, Yao JDC, Klimm K, et al. Efficacy of different B-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat intro-abdominal abscess model. Antimicrob Agents Chemother 1991; 35: 1243–4PubMedCrossRefGoogle Scholar
  59. 59.
    Trick WE, Weinstein RA, DeMarais PL, et al. Colonization of skilled-care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc 2001; 49: 270–6PubMedCrossRefGoogle Scholar
  60. 60.
    Gouby A, Neuwirth C, Bourg G, et al. Epidemiological study by pulsed-field gel electrophoresis of an outbreak of extended-spectrum beta-lactamase producing Klebsiella pneumoniae in a geriatric hospital. J Clin Microbiol 1994; 32: 301–5PubMedGoogle Scholar
  61. 61.
    Weller TM, MacKenzie FM, Forbes KJ. Molecular epidemiology of a large outbreak of multiresistant Klebsiella pneumoniae. J Med Microbiol 1997; 46: 921–6PubMedCrossRefGoogle Scholar
  62. 62.
    Ma L, Matsuo H, Ishii Y, et al. Characterization of cefotaxime-resistant Escherichia coli isolates from a nosocomial outbreak at three geriatric hospitals. J Infect Chemother 2002; 8: 155–62PubMedCrossRefGoogle Scholar
  63. 63.
    Hollander R, Ebke M, Barck H, et al. Asymptomatic carriage of Klebsiella pneumoniae producing extended-spectrum beta-lactamase by patients in a neurological early rehabilitation unit: management of an outbreak. J Hosp Infect 2001; 48: 207–13PubMedCrossRefGoogle Scholar
  64. 64.
    Rebuck JA, Olsen KM, Fey PD, et al. Characterization of an outbreak due to extended-spectrum beta-lactamase producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis 2000; 31: 1368–72PubMedCrossRefGoogle Scholar
  65. 65.
    Paterson DL, Singh N, Rihs JD, et al. Control of an outbreak of infection due to extended-spectrum beta-lactamase-producing Escherichia coli in a liver transplantation unit. Clin Infect Dis 2001; 33: 126–8PubMedCrossRefGoogle Scholar
  66. 66.
    Parasakthi N, Vadivelu J, Ariffin H, et al. Epidemiology and molecular characterization of nosocomially transmitted multidrug-resistant Klebsiella pneumoniae. Inf J Infect Dis 2000; 4: 123–8CrossRefGoogle Scholar
  67. 67.
    Revathi G, Shannon KP, Stapleton PD, et al. An outbreak of extended-spectrum, beta-lactamase-producing Salmonella seftenberg in a burns ward. J Hosp Infect 1998; 40: 295–302PubMedCrossRefGoogle Scholar
  68. 68.
    Kartali G, Tzelepi E, Pournaras S, et al. Outbreak of infections caused by Enterobacter cloacae producing the intergron-associated beta-lactamase IBC-1 in a neonatal intensive care unit of a Greek hospital. Antimicrob Agents Chemother 2002; 46: 1577–80PubMedCrossRefGoogle Scholar
  69. 69.
    Gonsalez-Vertiz A, Alcantar-Curiel D, Cuauhtli M, et al. Multiresistant extended-spectrum beta-lactamase-producing Klebsiella pneumoniae causing an outbreak of nosocomial bloodstream infection. Infect Control Hosp Epidemiol 2001; 22: 723–5CrossRefGoogle Scholar
  70. 70.
    Macrae MB, Shannon KP, Rayner DM, et al. A simultaneous outbreak on a neonatal unit of two strains of multiply antibiotic resistant Klebsiella pneumoniae controllable only by ward closure. J Hosp Infect 2001; 49: 183–92PubMedCrossRefGoogle Scholar
  71. 71.
    Royle J, Halasz S, Eagles G, et al. Outbreak of extended spectrum beta lactamase producing Klebsiella pneumoniae in a neonatal unit. Arch Dis Child Fetal Neonatal Ed 1999; 80: F64–8PubMedCrossRefGoogle Scholar
  72. 72.
    Palucha A, Mikiewicz B, Hryniewicz W, et al. Concurrent outbreaks of extended-spectrum β-lactamase-producing organisms of the family Enterobacteriaceae in a Warsaw hospital. J Antimicrob Chemother 1999; 44: 489–99PubMedCrossRefGoogle Scholar
  73. 73.
    Gaillot O, Maruejouls C, Abachin E, et al. Nosocomial outbreak of Klebsiella pneumoniae producing SHV-5 extended spectrum beta-lactamase, originating from a contaminated ultra-sonography coupling gel. J Clin Microbiol 1998; 36: 1357–60PubMedGoogle Scholar
  74. 74.
    Coovadia YM, Johnson AP, Bhana RH, et al. Multiresistant Klebsiella pneumoniae in a neonatal nursery: importance of maintenance of infection control policies and procedures in the prevention of outbreaks. J Hosp Infect 1992; 22: 197–205PubMedCrossRefGoogle Scholar
  75. 75.
    Gregersen N, VanNierop W, VonGottberg A, et al. Klebsiella pneumoniae with extended spectrum beta-lactamase activity associated with a necrotizing enterocolitis outbreak. Pediatr Infect Dis J 1999; 18: 963–7PubMedCrossRefGoogle Scholar
  76. 76.
    Wiener, J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281: 517: 523PubMedCrossRefGoogle Scholar
  77. 77.
    Fey PD, Moland, ES, Iwen PC, et al. Outbreak of extended-spectrum-lactamase-producing Klebsiella pneumoniae in pediatric liver transplant patients [abstract K-127]. 38th ICAAC; 1998 Sep 24–27; San Diego (CA)Google Scholar
  78. 78.
    Marchandin H, Carriere C, Sirot D, et al. TEM-24 produced by four different species of Enterobacteriaceae, including Providencia rettgeri, in a single patient. Antimicrob Agents Chemother 1999; 43: 2069–73PubMedGoogle Scholar
  79. 79.
    Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1998; 42: 53–8PubMedGoogle Scholar
  80. 80.
    Rahal JJ, Urban C, Horn D. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280: 1233–7PubMedCrossRefGoogle Scholar
  81. 81.
    Patterson JE, Hardin TC, Kelly CA, et al. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000; 21: 455–8PubMedCrossRefGoogle Scholar
  82. 82.
    Pangon B, Bizet C, Bure A, et al. In vivo selection of a cephamycin-resistant porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 B-lactamase. J Infect Dis 1989; 159: 1005–6PubMedCrossRefGoogle Scholar
  83. 83.
    Martinez-Martinez L, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998; 351: 797–9PubMedCrossRefGoogle Scholar
  84. 84.
    Bradford PA, Urban C, Mariano N, et al. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41: 563–9PubMedGoogle Scholar
  85. 85.
    Rebuck JA, Olsen KM, Fey PD, et al. In vitro activities of parenteral B-lactam antimicrobials against TEM-10-, TEM-26-and SHV-5-derived extended-spectrum β-lactamases expressed in an isogenic Escherichia coli host. J Antimicrob Chemother 2000; 46: 461–4PubMedCrossRefGoogle Scholar
  86. 86.
    Ambrose RG, Grasela TH, Jones RN. Antimicrobial susceptibility and pharmacodynamic comparison of piperacillintazobactam (P-T) and cefepime (PIM) against Enterobacteriaceae with extended-spectrum β-lactamase (ESBL) [abstract E-2266]. 41st ICAAC; 2001 Dec 16–19; Chicago (IL). Washington (DC): American Society for Microbiology, 2001Google Scholar
  87. 87.
    Andes D, Craig WA. Impact of extended-spectrum β-lactamase (ESBL) production on the activity of cefepime in a murine-thigh infection model [abstract A-1099]. 41st ICAAC; 2001 Dec 16–19; Chicago (IL). Washington (DC): American Society for Microbiology, 2001Google Scholar
  88. 88.
    Jacoby GA. Development of resistance in gram-negative pathogens: extended-spectrum-lactamases. In: Powers L (ed). Emerging pathogens in infectious disease: a hospital practice special report. Minneapolis: McGraw-Hill, 1999: 14–9Google Scholar
  89. 89.
    Thauvin-Elliopoulos C, Tripodi MF, Moellering Jr RC, et al. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum β-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997; 41: 1053–7Google Scholar
  90. 90.
    Pujol M, Pena C, Tubau F, et al. Emergence of an extended-spectrum β-lactamase producing Klebsiella pneumoniae following an increased use of cefepime in ICUs [abstract K-1180]. 41st ICAAC; 2001 Dec 16–19; Chicago (IL). Washington (DC): American Society for Microbiology, 2001Google Scholar
  91. 91.
    Mentec H, Vallois JM, Bure A, et al. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant. Antimicrob Agents Chemother 1992; 36: 1883–9PubMedCrossRefGoogle Scholar
  92. 92.
    Rice LB, Carias LL, Shlaes DM. In vivo efficacies of β-lactamβ-lactamase inhibitor combinations in Klebsiella pneumoniae and in vivo response to β-lactam therapy. J Infect Dis 1996; 173: 151–8PubMedCrossRefGoogle Scholar
  93. 93.
    Philippon A, Labia R, Jacoby G. Extended-spectrum β-lactamases. Antimicrob Agents Chemother 1989; 33: 1131–6PubMedCrossRefGoogle Scholar
  94. 94.
    Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30: 473–8PubMedCrossRefGoogle Scholar
  95. 95.
    Spanu T, Luzzaro F, Perilli M, et al. The Italian ESBL Study Group. Occurrence of extended-spectrum β-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to β-lactams and other antimicrobial drugs. Antimicrob Agents Chemother 2002; 46: 196–202Google Scholar
  96. 96.
    Martinez-Martinez L, Hernandez-Alles S, Alberti S, et al. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1996; 40: 342–8PubMedGoogle Scholar
  97. 97.
    Jacoby GA, Sutton L. Properties of plasmids responsible for production of extended-spectrum β-lactamases. Antimicrob Agents Chemother 1991; 35: 164–9PubMedCrossRefGoogle Scholar
  98. 98.
    Poirel L, Le Thomas I, Naas T, et al. Biochemical sequence analyses of GES-1, a novel Class A extended-spectrum β-lactamase, and the Class 1 integron In52 from Klebsiella pneumoniae. Antimicrob Agents Chemother 2000; 44: 622–32PubMedCrossRefGoogle Scholar
  99. 99.
    Moellering Jr RC, Eliopoulos GM, Sentochnik DE. The carbapenems: new broad spectrum β-lactam antibiotics. J Antimicrob Chemother 1989; 24 Suppl A: 1–7PubMedCrossRefGoogle Scholar
  100. 100.
    Edwards JR, Turner PJ. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis 1995; 96: 5–10Google Scholar
  101. 101.
    Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460–3PubMedCrossRefGoogle Scholar
  102. 102.
    Wong-Beringer A. Therapeutic challenges associated with extended-spectrum β-lactams-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001; 21: 583–92PubMedCrossRefGoogle Scholar
  103. 103.
    Paterson DL, Ko WC, Mohapatra S, et al. Klebsiella pneumoniae bacteremia: impact of extended spectrum β-lactamase (ESBL) production in aglobal study of 216patients [abstract J-210]. 37th ICAAC; 1997 Sep 28–Oct 1; Toronto. Washington (DC): American Society for Microbiology, 1997Google Scholar
  104. 104.
    Black JA, Moland ES, Lockhart TJ, et al. Faropenem: Activity against ESBL, AMPC, and other β-lactamase-producing Enterobacteriaceae [abstract E-791]. 41st ICAAC; 2001 Dec 16–19; Chicago (IL). Washington (DC): American Society for Microbiology, 2001Google Scholar
  105. 105.
    Olsen KM, McNabb JC, Fey PD, et al. In vitro activities of MK-0826 and parenteral β-lactam antimicrobials against clinical isolates of ESBL-producing Klebsiella pneumoniae and in an isogenic host [abstract E-807]. 41st ICAAC; 2001 Dec 16–19; Chicago (IL). Washington (DC): American Society for Microbiology, 2001Google Scholar
  106. 106.
    Senda K, Arakawa Y, Ichiyama S, et al. PCR detection of metallo: lactamase gene (bla imp) in gram-negative rods resistant to broad-spectrum β-lactams. J Clin Microbiol 1996; 34: 2909–13PubMedGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  1. 1.Department of Internal MedicineUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations